Skip to main content

Advertisement

SpringerLink
Log in

Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the ideal treatment for several diseases. However, the morbidity and mortality associated with the procedure might limit its widespread use; therefore, we implemented reduced BUCY2 as conditioning method along with the use of G-CSF-primed bone marrow (G-BM) in order to reduce complications, including graft-versus-host-disease (GVHD), and to improve survival in these patients. An analysis of transplant characteristics, complications, and survival of patients undergoing an allo-HSCT using this conditioning regimen (busulfan 12 mg/kg and cyclophosphamide 80 mg/kg) plus G-BM was performed. Forty patients were included from 1999 to 2015. All of them had a HLA-matched donor, with a median age of 32 years (range 16–59), and 55% were male. The most frequent diagnosis was myelodysplastic syndrome (MDS) in 14 patients (35%), followed by acute lymphoid leukemia (ALL) in 12 (30%). The mean of CD34+ was 2.09 × 106/kg. The mean time to neutrophil and platelet recovery was 20 and 18 days, respectively. The most common toxicity was mucositis (75%) with grade III–IV in 53% of cases. Acute GVHD appeared in 12.5 and 35% of patients developed chronic GVHD. Transplant-related mortality (TRM) was 10%. Five-year relapse-free survival was 69%, and the 5-year overall survival was 69.5%. Our conditioning method along with G-BM preserves an immunosuppressive and myeloablative effect allowing eradication of the malignant clone and achieving adequate bone marrow engraftment with acceptable toxicity, low incidence of GVHD, and low TRM, representing a favorable alternative for allo-HSCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pasquini MC, Zhu X (2015) Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR Summary Slides. Available at: http://www.cibmtr.org

  2. Khera N, Zeliadt SB, Lee SJ (2012) Economics of hematopoietic cell transplantation. Blood 120(8):1545–1551

    Article  CAS  PubMed  Google Scholar 

  3. Tanaka Y, Kurosawa S, Tajima K, Tanaka T, Ito R, Inoue Y et al (2016) Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 51:553–559

    Article  CAS  PubMed  Google Scholar 

  4. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al (2011) Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 29(16):2230–2239

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sengeløv H, Gerds TA, Brændstrup P, Kornblit B, Mortensen BK, Petersen SL et al (2013) Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning. Bone Marrow Transplant 48:1185–1191

    Article  PubMed  Google Scholar 

  6. Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M (2012) Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 13(10):1035–1044

    Article  PubMed  Google Scholar 

  7. Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y et al (2010) Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 116:1369–1376

    Article  CAS  PubMed  Google Scholar 

  8. Woolfrey A, Lee SJ, Gooley TA, Malkki M, Martin PJ, Pagel JM et al (2010) HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. Biol Blood Marrow Transplant. 16(10):1382–1387

    Article  PubMed  PubMed Central  Google Scholar 

  9. Gyurkocza B, Sandmaier BM (2014) Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 124(3):344–353

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309(22):1347–1353

    Article  CAS  PubMed  Google Scholar 

  11. Tutschka PJ, Copelan EA, Klein JP (1987) Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70(5):1382–1388

    CAS  PubMed  Google Scholar 

  12. Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW et al (2013) Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 31(6):701–709

    Article  CAS  PubMed  Google Scholar 

  13. Pessach I, Resnick I, Shimoni A, Nagler A (2015) G-CSF-primed BM for allogeneic SCT: revisited. Bone Marrow Transplant 50(7):892–898

    Article  CAS  PubMed  Google Scholar 

  14. Deotare U, Al-Dawsari G, Couban S, Lipton JH (2015) G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept. Bone Marrow Transplant 50(9):1150–1156

    Article  CAS  PubMed  Google Scholar 

  15. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al (2015) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 21(3):389–401.e1

    Article  PubMed  Google Scholar 

  16. Vigorito A, Campregher P, Storer B, Carpenter PA, Moravec CK, Kiem HP et al (2009) Evaluation of NIH consensus criteria for classification of late acute and chronic GVDH. Blood 114(3):702–708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Rubio MT, Labopin M, Blaise D, Socié G, Rojas Contreras R, Chevallier P et al (2015) The impact of graft-cersus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the acute leukemia working party of the European group for blood and marrow transplantation. Haematologica 100:683–689

    Article  PubMed  PubMed Central  Google Scholar 

  18. Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau JL et al (2014) Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution’s three decade experience. Biol Blood Marrow Transplant. 20(8):1217–1223

    Article  PubMed  Google Scholar 

  19. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L et al (2011) Myeloablative reduced-toxicity iv busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant. 17(10):1490–1496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M (2015) Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the acute leukemia working party of the EBMT. Haematologica 100:859–869

    Article  PubMed  PubMed Central  Google Scholar 

  21. Serody JS, Sparks SD, Lin Y, Capel EJ, Bigelow SH, Kirby SL et al (2000) Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 6:434–440

    Article  CAS  PubMed  Google Scholar 

  22. Morton J, Hutchins C, Durrant S (2001) Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significant less graft-versus-host-disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 98:3186–3191

    Article  CAS  PubMed  Google Scholar 

  23. Zhao XS, Chen Y, Zhao XY, Liu DH, Xu LP, Wang Y et al (2013) Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia. Clin Transpl 27(6):844–851

    Article  Google Scholar 

  24. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH (2001) Acute and chronic graft-versus-host disease after allogeneic peripheral blood stem cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 19:3685–3691

    Article  CAS  PubMed  Google Scholar 

  25. Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C et al (2014) Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 4:CD010189

    Google Scholar 

  26. Besinger W, Martin P, Storer B, Clift R, Forman SJ, Negrin R et al (2001) Transplantation of bone marrow cells as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175–181

    Article  Google Scholar 

  27. To LB, Haylock DN, Simmons PJ, Juttner CA (1997) The biology and clinical uses of blood stem cells. Blood 89(7):2233–2258

    CAS  PubMed  Google Scholar 

  28. To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL et al (1990) Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 18(5):442–447

    CAS  PubMed  Google Scholar 

  29. Lemoli RM, Tafuri A, Fortuna A, Petrucci MT, Ricciardi MR, Catani L et al (1997) Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Blood 89(4):1189–1196

    CAS  PubMed  Google Scholar 

  30. Johnsen HE, Hansen PB, Plesner T, Jensen L, Gaarsdal E, Andersen H et al (1992) Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor. Bone Marrow Transplant 10(3):229–234

    CAS  PubMed  Google Scholar 

  31. Damiani D, Fanin RF, Silvestri F, Grimaz S, Infanti L, Geromin A et al (1997) Randomized trial of autologous filgrastim- primed bone marrow transplantation versus filgrastim mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 90:36–42

    CAS  PubMed  Google Scholar 

  32. Ji SQ, Chen HR, Xun CQ, Wang HX, Pan SP, Xiao MH (2001) The effect of G-CSF estimulated donor marrow on engraftment and incidence of graft-versus-host disease in allogeneic bone marrow transplantation. Clin Transpl 15:317–323

    Article  CAS  Google Scholar 

  33. Ji SQ, Chen HR, Wang HX, Yan HM, Pan S, Xun CQ (2002) Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 8:261–267

    Article  PubMed  Google Scholar 

  34. Ostronoff M, Ostronoff F, Souto Maior P, Matias C, Calixto R, Sucupira A et al (2006) Pilot study of allogeneic G-CSF-stimulated bone marrow transplantation: harvest, engraftment, and graft-versus-host disease. Biol Blood Marrow Transplant 12(7):729–733

    Article  CAS  PubMed  Google Scholar 

  35. Elfenbein GJ, Sackstein R, Oblon DJ (2004) Do G-CSF mobilized, peripheral blood-derived stem cells from healthy, HLA-identical donors really engraft more rapidly than do G-CSF primed, bone marrow-derived stem cells? No! Blood Cells Mol Dis 32(1):106–111

    Article  CAS  PubMed  Google Scholar 

  36. Li Y, Jiang M, Xu C, Chen J, Li B, Wang J et al (2015) Granulocyte colony-stimulating factor-primed bone marrow: an excellent stem-cell source for transplantationin acute myelocytic leukemia and chronic myelocytic leukemia. Chin Med J 128(1):20–24

    Article  PubMed  PubMed Central  Google Scholar 

  37. Danby RD, Zhang W, Medd P, Littlewood TJ, Peniket A, Rocha V et al (2016) High proportions of regulatory T cells in PBSC grafts predict improved survival after allogeneic haematopoietic SCT. Bone Marrow Transplant 51(1):110–118

    Article  CAS  PubMed  Google Scholar 

  38. Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M et al (2016) Filgrastim-stimulated bone marrow compared with filgrastim-mobilized peripheral blood in myeloablative sibling allografting for patients with hematologic malignancies: a randomized Canadian blood and marrow transplant group study. Biol Blood Marrow Transplant 22:1410–1415

    Article  CAS  PubMed  Google Scholar 

  39. Sun LX, Zhao YT, Chang YJ (2012) Peripheral blood stem cell transplantation or bone marrow transplant in allogeneic settings: which should be chosen? Leuk Res 36(5):e116–e117

    Article  PubMed  Google Scholar 

  40. Zhang C, Zhang X, Chen XH (2013) Cellular mechanism for granulocyte-colony stimulating factor in the prevention of graft-versus-host disease in combined bone marrow and peripheral blood transplantation for hematological malignancies: the composition in collection. Transfus Apher Sci 48(1):3–9

    Article  PubMed  Google Scholar 

  41. Piccirilo C, Shevach E (2004) Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 16:81–88

    Article  Google Scholar 

  42. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J et al (2006) High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108(4):1291–1297

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H et al (2013) Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia. Bone Marrow Transplant 48:1198–1204

    Article  CAS  PubMed  Google Scholar 

  44. Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H et al (2013) Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan transplant outcome registry. Bone Marrow Transplant 48:529–536

    Article  CAS  PubMed  Google Scholar 

  45. Mohty M, Malard F, Blaise D, Milpied N, Furst S, Tabrizi R et al (2015) Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial. Cancer 121(4):562–569

    Article  CAS  PubMed  Google Scholar 

  46. Sibai H, Falcone U, Deotare U, Michelis FV, Uhm J, Gupta V et al (2016) Myeloablative versus reduced-intensity conditioning in patients with myeloid malignancies: a propensity score matched analysis. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2016.08.030

  47. Scott BL, Pasquini MC, Logan B, Wu J, Devine S, Porter DL, et al. (2015) Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): blood and marrow transplant clinical trials network (BMT CTN) 0901. Blood; 126: LBA-8

Download references

Acknowledgments

We thank the non-governmental and non-profit organization “Unidos…Asociacion Pro Trasplante de Medula Osea”, in Mexico City, for facilitating most of our patients the acquisition of medications and providing emotional support.

Author information

Authors and Affiliations

  1. Stem Cell Transplantation Program, Hematology and Oncology Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

    Eucario Leon Rodriguez & Monica M. Rivera Franco

  2. Internal Medicine Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

    Sandra I. Perez Alvarez

Authors
  1. Eucario Leon Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica M. Rivera Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandra I. Perez Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eucario Leon Rodriguez.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leon Rodriguez, E., Rivera Franco, M.M. & Perez Alvarez, S.I. Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT. Ann Hematol 96, 1525–1531 (2017). https://doi.org/10.1007/s00277-017-3056-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3056-0

Keywords

Search

Navigation